Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Reich K, et al. Among authors: langley rg. Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Lancet. 2021. PMID: 33549193 Clinical Trial.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Gordon KB, et al. Among authors: langley rg. J Am Acad Dermatol. 2006 Oct;55(4):598-606. doi: 10.1016/j.jaad.2006.05.027. Epub 2006 Aug 10. J Am Acad Dermatol. 2006. PMID: 17010738 Clinical Trial.
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, Ferrándiz C, Sinclair R, Saurat JH; CLEAR Multinational Study Group. Sterry W, et al. Among authors: langley rg. J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56. doi: 10.1111/j.1610-0387.2006.06111.x. J Dtsch Dermatol Ges. 2006. PMID: 17081270 Clinical Trial. English, German.
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. Krueger GG, et al. Among authors: langley rg. N Engl J Med. 2007 Feb 8;356(6):580-92. doi: 10.1056/NEJMoa062382. N Engl J Med. 2007. PMID: 17287478 Free article. Clinical Trial.
213 results